Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury.
Procarbazine is a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals that damage DNA through an alkylation reaction.
Procarbazine is a benzamide obtained by formal condensation of the carboxy group of 4-[(2-dimethylhydrazine)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for the treatment of Hodgkin’s lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. It has a role as an antineoplastic agent. It is a member of hydrazines and a member of benzamides. It is a conjugate base of procarbazine(1+).
Procarbazine Hydrochloride is the hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals that damage DNA through an alkylation reaction.
Mechanism of Action
The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit the transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto-oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA. Procarbazine is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands – directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Procarbazine is cell-phase specific for the S phase of cell division.
or
O-6-Methylguanine was measured in the blood leukocyte DNA of seven patients with Hodgkin’s or non-Hodgkin’s lymphoma during therapeutic exposure to procarbazine involving three daily p.o. doses (50 mg each) for 10 days (corresponding to 2.1 mg/kg/day for a 70-kg human). Adduct accumulation was observed in all seven cases, reaching levels up to 0.28 fmol/microgram of DNA (0.45 umol/mol of guanine). In one individual, maximal levels of adduct were reached after 7 days of exposure, followed by a steady decline, whereas in all other individuals continuous accumulation was observed throughout the exposure period. In four individuals for which data were available for day 11 (12 to 16 hr after the final intake of procarbazine), decreased amounts of O-6-methylguanine were observed relative to the last previous measurements. The accumulation of O-6-methylguanine was linearly correlated with the cumulative dose of procarbazine, with a slope of 0.011 fmol of O-6-methylguanine/microgram of DNA per mg/kg of body weight or 2.68×10-4 fmol of O-6-methylguanine DNA per mg/sq m. Two hr after the administration of single p.o. doses of l to 10 mg/kg of procarbazine to rats, O-6-methylguanine formation in leukocyte DNA was just under half that in liver DNA and showed a linear relationship with dose with a slope of 0.017 fmol/microgram of DNA per mg/kg of body weight or 5.67×10-4 fmol of O-6-methylguanine/microgram of DNA per mg/sq m. A negative correlation between the rate of accumulation of O-6-methylguanine in different individuals and lymphocyte O-6-alkylguanine-DNA alkyltransferase was observed, demonstrating a probable protective effect of O-6-alkylguanine-DNA alkyltransferase against the accumulation of O-6-methylguanine during exposure to methylating agents. This observation supports the suggestion of a possible role of procarbazine-induced O-6-methylguanine in the pathogenesis of acute nonlymphocytic leukemia appearing after treatment with chemotherapeutic protocols which include procarbazine, based on the finding of low lymphocyte O-6-alkylguanine-DNA alkyltransferase levels in patients with such therapy-related neoplastic disease. Lymphocyte O-6-alkylguanine-DNA alkyltransferase levels were mainly in the range of 5 to 10 fmol/micrograms of DNA and showed no consistent variation during procarbazine exposure.
Indications
- For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin’s disease.
- Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury.
- Non-Hodgkin’s Lymphoma (NHL)
- Oligodendrogliomas
- Primary Central Nervous System Lymphoma (PCNSL)
- Stage III Hodgkin’s Disease
- Stage IV Hodgkin’s Disease
- Non-Hodgkin’s Lymphoma (NHL)
- Oligodendrogliomas
- Primary Central Nervous System Lymphoma (PCNSL)
- Stage III Hodgkin’s Disease
- Stage IV Hodgkin’s Disease
Contraindication
The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:
- is allergic to procarbazine or to any of the ingredients of the medication
- has severe depletion of neutrophils (white blood cells), platelets, or red blood cell
- a bacterial infection
- opportunistic fungal infection
- an infection due to a protozoa organism
- decreased function of bone marrow
- anemia
- increased risk of bleeding due to clotting disorder
- decreased blood platelets
- low levels of white blood cells
- alcoholism
- a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
- liver problems
- pregnancy
- a patient who is producing milk and breastfeeding
- kidney disease with likely reduction in kidney function
- an increased risk of developing an uncommon viral infection called an opportunistic infection
Dosage
Strengths: 50 mg
Hodgkin’s Disease
As a single agent:
- Initial dose: Single or divided doses of 2 to 4 mg/kg/day orally for one week (to minimize nausea and vomiting experienced by a high percentage of patients beginning therapy)
- Maintenance dose: 4 to 6 mg/kg/day orally until a maximum response is obtained or until the white blood count falls below 4000 or the platelets fall below 100,000; when the maximum response is obtained the dose may be maintained at 1 to 2 mg/kg/day orally
- Discontinue therapy for hematologic or other toxicity until satisfactory recovery, then resume therapy (at the discretion of the physician based on patient evaluation and laboratory studies) at 1 to 2 mg/kg/day
In combination with other anticancer drugs:
- The dose of this drug should be reduced (e.g., in the MOPP regimen, the dose is 100 mg/m2/day for 14 days)
Usual Pediatric Dose for Hodgkin’s Disease
Close clinical monitoring is necessary to minimize toxicity (e.g., tremors, coma, convulsions). Dosage should be individualized. The following dosage schedule is provided as a guideline only:
- Initial dose: 50 mg/m2/day orally for the first week
- Maintenance dose: 100 mg/m2/day orally until a maximum response is obtained or until leukopenia or thrombocytopenia occurs; when the maximum response is obtained the dose may be maintained at 50 mg/m2/day orally
- Discontinue therapy for hematologic or other toxicity until satisfactory recovery, then resume therapy (at the discretion of the physician based on patient evaluation and laboratory studies).
Side Effects
The Most Common
- nausea, vomiting,
- leukopenia and thrombocytopenia
- somnolence, lethargy, hallucinations, confusion,
- agitation,
- cerebellar ataxia,
- paresthesias, myalgia, a
- decrease of deep tendon reflexes,
- hypotension and allergic skin reactions.
- arthralgia, fever, weakness,
- dermatitis, coma, alopecia, and convulsions.
- anorexia, stomatitis, diarrhea, drowsiness, and depression.
- bone marrow depression,
- hemolysis, bleeding tendencies, psychoses, dizziness,
- peripheral neuropathy, tremors, flu-like syndrome,
- pulmonary reactions, tachycardia,
- ocular defects such as blurred vision and
- papilledema, impaired liver function,
More Common
- shortness of breath, pneumonitis, and productive cough.
- peripheral leukocyte and platelet counts,
- optic neuroretinitis and pulmonary eosinophilia.
- anemia, dry mouth, dysphagia,
- constipation, fatigue pruritus,
- herpes, hyperpigmentation, flushing, intercurrent infections,
- pleura effusion, edema,
- jaundice, headache,
- apprehension, nervousness,
- inability to focus, insomnia,
- pyrexia, hypersensitivity reactions,
- hemorrhage, pancytopenia eosinophilia,
- petechiae, purpura, epistaxis,
- hemoptysis, hematemesis, melena,
- nystagmus, urticaria, hearing loss,
- \diaphoresis, chills, hoarseness,
- slurred speech, enteritis, nightmares, falling,
- unsteadiness, abdominal pain, syncope, retinal hemorrhage,
- photophobia, diplopia, hematuria,
- urinary frequency, nocturia, foot drop and fetal harm.
- palpitations, sweating,
- hypotension and dyspnea.
Rare
- cough
- diarrhea
- fainting
- fever
- fast, slow, or pounding heartbeat
- hallucinations (hearing or seeing things that aren’t there)
- missing menstrual periods
- shortness of breath
- signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don’t stop bleeding)
- signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide)
- signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
- lung infection (e.g., difficulty breathing, shortness of breath, wheezing)
- skin rash, hives, or itching
- sores in mouth and on lips
- symptoms of a urinary tract infection (e.g. pain when urinating, urinating more often than usual, low back or flank pain)
- tingling or numbness of fingers or toes
- tiredness or weakness (continuing)
- unusual infections (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness)
- vision changes (e.g., blurred vision, increased sensitivity to sunlight)
Drug interactions
| DRUG | INTERACTION |
|---|---|
| 1,2-Benzodiazepine | The risk or severity of adverse effects can be increased when Procarbazine is combined with 1,2-Benzodiazepine. |
| Abatacept | The risk or severity of adverse effects can be increased when Procarbazine is combined with Abatacept. |
| Abciximab | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Abciximab. |
| Acarbose | Procarbazine may increase the hypoglycemic activities of Acarbose. |
| Acebutolol | Procarbazine may increase the hypotensive activities of Acebutolol. |
| Acenocoumarol | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Acenocoumarol. |
| Acetazolamide | The risk or severity of adverse effects can be increased when Acetazolamide is combined with Procarbazine. |
| Acetohexamide | Procarbazine may increase the hypoglycemic activities of Acetohexamide. |
| Acetophenazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Acetophenazine. |
| Acetylsalicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Acetylsalicylic acid. |
| Acipimox | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Acipimox. |
| Aclidinium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Procarbazine. |
| Adenovirus type | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Procarbazine. |
| Agomelatine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Agomelatine. |
| Albiglutide | Procarbazine may increase the hypoglycemic activities of Albiglutide. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Procarbazine. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Procarbazine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine. |
| Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procarbazine. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Procarbazine. |
| Alimemazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Alimemazine. |
| Aliskiren | Procarbazine may increase the hypotensive activities of Aliskiren. |
| Allogeneic processed | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Procarbazine. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Procarbazine. |
| Almotriptan | The metabolism of Almotriptan can be decreased when combined with Procarbazine. |
| Alogliptin | Procarbazine may increase the hypoglycemic activities of Alogliptin. |
| Alosetron | The risk or severity of adverse effects can be increased when Alosetron is combined with Procarbazine. |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Procarbazine. |
| Alteplase | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Alteplase. |
| Altretamine | Altretamine may increase the orthostatic hypotensive activities of Procarbazine. |
| Alverine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Alverine. |
| Amantadine | The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Procarbazine. |
| Ambrisentan | Procarbazine may increase the hypotensive activities of Ambrisentan. |
| Amifostine | Procarbazine may increase the orthostatic hypotensive activities of Amifostine. |
| Amiloride | Procarbazine may increase the orthostatic hypotensive activities of Amiloride. |
| Amiodarone | Procarbazine may increase the orthostatic hypotensive activities of Amiodarone. |
| Amisulpride | The risk or severity of adverse effects can be increased when Procarbazine is combined with Amisulpride. |
| Amitriptyline | Procarbazine may increase the serotonergic activities of Amitriptyline. |
| Amitriptylinoxide | Procarbazine may increase the serotonergic activities of Amitriptylinoxide. |
| Amlodipine | Procarbazine may increase the hypotensive activities of Amlodipine. |
| Amobarbital | The risk or severity of adverse effects can be increased when Procarbazine is combined with Amobarbital. |
| Amoxapine | Procarbazine may increase the serotonergic activities of Amoxapine. |
| Amphetamine | Procarbazine may increase the hypertensive activities of Amphetamine. |
| Amphotericin B | Procarbazine may increase the orthostatic hypotensive activities of Amphotericin B. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Procarbazine. |
| Amyl Nitrite | Procarbazine may increase the orthostatic hypotensive activities of Amyl Nitrite. |
| Anagrelide | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Anagrelide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Procarbazine. |
| Ancrod | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ancrod. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Anifrolumab. |
| Anisotropine methylbromide | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide. |
| Anistreplase | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Anistreplase. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Procarbazine. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Procarbazine. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Procarbazine is combined with Antilymphocyte immunoglobulin (horse). |
| Antithrombin Alfa | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Antithrombin Alfa. |
| Antithrombin III human | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Antithrombin III human. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Procarbazine. |
| Apixaban | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Apixaban. |
| Apomorphine | Procarbazine may increase the orthostatic hypotensive activities of Apomorphine. |
| Apraclonidine | Procarbazine may increase the alpha-adrenergic activities of Apraclonidine. |
| Apremilast | The risk or severity of adverse effects can be increased when Procarbazine is combined with Apremilast. |
| Apronalide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Apronalide. |
| Arbutamine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Arbutamine. |
| Ardeparin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ardeparin. |
| Arformoterol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Arformoterol. |
| Argatroban | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Argatroban. |
| Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Procarbazine. |
| Aripiprazole lauroxil | The risk or severity of serotonin syndrome can be increased when Aripiprazole lauroxil is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Articaine. |
| Asenapine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Asenapine. |
| AstraZeneca | The therapeutic efficacy of the AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Procarbazine. |
| Atenolol | Procarbazine may increase the hypotensive activities of Atenolol. |
| Atomoxetine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Atomoxetine. |
| Atorvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Atorvastatin is combined with Procarbazine. |
| Atracurium | The risk or severity of adverse effects can be increased when Procarbazine is combined with Atracurium. |
| Atracurium besylate | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Procarbazine. |
| Atropine | The risk or severity of hypertension can be increased when Procarbazine is combined with Atropine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Procarbazine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Procarbazine. |
| Azelastine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Azilsartan medoxomil | Procarbazine may increase the hypotensive activities of Azilsartan medoxomil. |
| Bacillus calmette-guerin | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Procarbazine. |
| Bacillus calmette-guerin | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Procarbazine. |
| Bacillus calmette-guerin | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Procarbazine. |
| Baclofen | The risk or severity of hypotension can be increased when Baclofen is combined with Procarbazine. |
| Baricitinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Procarbazine. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Procarbazine. |
| Beclomethasone | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Procarbazine. |
| Belatacept | The risk or severity of adverse effects can be increased when Procarbazine is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Procarbazine is combined with Belinostat. |
| Belladonna | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Belladonna. |
| Belumosudil | The risk or severity of adverse effects can be increased when Procarbazine is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Bemiparin. |
| Benazepril | Procarbazine may increase the hypotensive activities of Benazepril. |
| Bendamustine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bendamustine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Procarbazine. |
| Betaxolol | Procarbazine may increase the hypotensive activities of Betaxolol. |
| Bethanidine | Procarbazine may increase the hypotensive activities of Bethanidine. |
| Betrixaban | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Betrixaban. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Procarbazine. |
| Bezafibrate | Procarbazine may increase the hepatotoxic activities of Bezafibrate. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bimekizumab. |
| Biperiden | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Biperiden. |
| Bisoprolol | Procarbazine may increase the hypotensive activities of Bisoprolol. |
| Bivalirudin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Bivalirudin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Procarbazine. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Blinatumomab. |
| Bordetella pertussis | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Procarbazine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Procarbazine. |
| Bosentan | Procarbazine may increase the hypotensive activities of Bosentan. |
| Bosutinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bosutinib. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Procarbazine. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Botulinum toxin type B is combined with Procarbazine. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Procarbazine is combined with Brentuximab vedotin. |
| Bretylium | Procarbazine may increase the hypotensive activities of Bretylium. |
| Brexanolone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Brexanolone. |
| Brexpiprazole | The metabolism of Brexpiprazole can be decreased when combined with Procarbazine. |
| Brimonidine | The metabolism of Brimonidine can be decreased when combined with Procarbazine. |
| Brivaracetam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Brivaracetam. |
| Brodalumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Brodalumab. |
| Bromazepam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bromazepam. |
| Bromocriptine | Procarbazine may increase the hypertensive activities of Bromocriptine. |
| Bromperidol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bromperidol. |
| Brompheniramine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Buclizine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Buclizine. |
| Budesonide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Budesonide. |
| Bumetanide | Procarbazine may increase the orthostatic hypotensive activities of Bumetanide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Bupivacaine. |
| Buprenorphine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Bupropion | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bupropion. |
| Buspirone | The risk or severity of hypertension can be increased when Procarbazine is combined with Buspirone. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Procarbazine. |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Procarbazine. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Butacaine. |
| Butalbital | The risk or severity of adverse effects can be increased when Butalbital is combined with Procarbazine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Butamben. |
| Butaperazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Butaperazine. |
| Butobarbital | The risk or severity of adverse effects can be increased when Procarbazine is combined with Butobarbital. |
| Butorphanol | The risk or severity of adverse effects can be increased when Butorphanol is combined with Procarbazine. |
| Butriptyline | Procarbazine may increase the serotonergic activities of Butriptyline. |
| Butylscopolamine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Procarbazine is combined with Cabazitaxel. |
| Cabergoline | The metabolism of Cabergoline can be decreased when combined with Procarbazine. |
| Canagliflozin | Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin. |
| Canakinumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Canakinumab. |
| Candesartan cilexetil | Procarbazine may increase the hypotensive activities of Candesartan cilexetil. |
| Cangrelor | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Cangrelor. |
| Cannabidiol | The metabolism of Cannabidiol can be decreased when combined with Procarbazine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Procarbazine. |
| Caplacizumab | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Caplacizumab. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Capsaicin. |
| Captopril | Procarbazine may increase the hypotensive activities of Captopril. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Procarbazine. |
| Carbetocin | Procarbazine may increase the orthostatic hypotensive activities of Carbetocin. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Procarbazine. |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Procarbazine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Procarbazine. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Carfilzomib. |
| Cariprazine | The metabolism of Cariprazine can be decreased when combined with Procarbazine. |
| Carisoprodol | The risk or severity of adverse effects can be increased when Carisoprodol is combined with Procarbazine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Procarbazine. |
| Carvedilol | Procarbazine may increase the hypotensive activities of Carvedilol. |
| Celiprolol | Procarbazine may increase the hypotensive activities of Celiprolol. |
| Cerivastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Procarbazine. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of adverse effects can be increased when Cetirizine is combined with Procarbazine. |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Procarbazine is combined with Chloral hydrate. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Procarbazine. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Procarbazine. |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Procarbazine. |
| Chlormezanone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Chlormezanone. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Procarbazine. |
| Chlorothiazide | Procarbazine may increase the hypotensive activities of Chlorothiazide. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Procarbazine. |
| Chlorpromazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Chlorpromazine. |
| Chlorpropamide | Procarbazine may increase the hypoglycemic activities of Chlorpropamide. |
| Chlorprothixene | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Chlorthalidone | Procarbazine may increase the hypotensive activities of Chlorthalidone. |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Procarbazine. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ciclesonide. |
| Cilazapril | Procarbazine may increase the hypotensive activities of Cilazapril. |
| Cilostazol | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Cilostazol. |
| Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Procarbazine. |
| Dantrolene | The risk or severity of adverse effects can be increased when Procarbazine is combined with Dantrolene. |
| Dapagliflozin | Procarbazine may increase the orthostatic hypotensive activities of Dapagliflozin. |
| Daptomycin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Procarbazine. |
| Daridorexant | The risk or severity of CNS depression can be increased when Procarbazine is combined with Daridorexant. |
| Darifenacin | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin. |
| Dasatinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Dasatinib. |
| Dasiglucagon | Procarbazine may increase the hypotensive activities of Dasiglucagon. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine. |
| Debrisoquine | Procarbazine may increase the hypotensive activities of Debrisoquine. |
| Decamethonium | The risk or severity of adverse effects can be increased when Procarbazine is combined with Decamethonium. |
| Decitabine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Decitabine. |
| Defibrotide | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Defibrotide. |
| Deflazacort | The risk or severity of adverse effects can be increased when Procarbazine is combined with Deflazacort. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Procarbazine. |
| Deserpidine | Procarbazine may increase the hypotensive activities of Deserpidine. |
| Desflurane | The risk or severity of adverse effects can be increased when Desflurane is combined with Procarbazine. |
| Desipramine | Procarbazine may increase the serotonergic activities of Desipramine. |
| Desirudin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Desirudin. |
| Desloratadine | The risk or severity of adverse effects can be increased when Desloratadine is combined with Procarbazine. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Procarbazine. |
| Desvenlafaxine | Procarbazine may increase the serotonergic activities of Desvenlafaxine. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Deucravacitinib. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Deutetrabenazine. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Dexamethasone. |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procarbazine. |
| Dexfenfluramine | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Dexfenfluramine. |
| Dexmedetomidine | Procarbazine may increase the orthostatic hypotensive activities of Dexmedetomidine. |
| Dexmethylphenidate | Procarbazine may increase the hypertensive activities of Dexmethylphenidate. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Procarbazine. |
| Dextran | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Dextran. |
| Dextroamphetamine | Procarbazine may increase the hypertensive activities of Dextroamphetamine. |
| Dextromethorphan | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Dextromethorphan. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Procarbazine. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Procarbazine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with Procarbazine. |
| Diazepam | The risk or severity of adverse effects can be increased when Diazepam is combined with Procarbazine. |
| Diazoxide | Procarbazine may increase the hypotensive activities of Diazoxide. |
| Dibenzepin | Procarbazine may increase the serotonergic activities of Dibenzepin |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Duloxetine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Dyclonine. |
| Ebola Zaire | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Procarbazine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Edetic acid. |
| Edoxaban | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Edoxaban. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Procarbazine. |
| Efavirenz | The risk or severity of adverse effects can be increased when Efavirenz is combined with Procarbazine. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Procarbazine. |
| Eluxadoline | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Eluxadoline. |
| Emapalumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Emapalumab. |
| Empagliflozin | Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin. |
| Enalapril | Procarbazine may increase the hypotensive activities of Enalapril. |
| Enalaprilat | Procarbazine may increase the hypotensive activities of Enalaprilat. |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Procarbazine. |
| Enoxaparin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Enoxaparin. |
| Entacapone | The risk or severity of adverse effects can be increased when Entacapone is combined with Procarbazine. |
| Epinastine | The risk or severity of adverse effects can be increased when Epinastine is combined with Procarbazine. |
| Epinephrine | Procarbazine may increase the hypertensive activities of Epinephrine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Procarbazine. |
| Eplerenone | Procarbazine may increase the hypotensive activities of Eplerenone. |
| Epoprostenol | Procarbazine may increase the hypotensive activities of Epoprostenol. |
| Eprosartan | Procarbazine may increase the hypotensive activities of Eprosartan. |
| Eptifibatide | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Eptifibatide. |
| Ergoloid mesylate | The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine. |
| Ergometrine | Procarbazine may increase the hypertensive activities of Ergometrine. |
| Ergotamine | The metabolism of Ergotamine can be decreased when combined with Procarbazine. |
| Eribulin | The risk or severity of adverse effects can be increased when Procarbazine is combined with Eribulin. |
| Ertugliflozin | Procarbazine may increase the hypoglycemic activities of Ertugliflozin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Procarbazine. |
| Escitalopram | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Escitalopram. |
| Esketamine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Esketamine. |
| Eslicarbazepine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Eslicarbazepine. |
| Eslicarbazepine acetate | The risk or severity of adverse effects can be increased when Procarbazine is combined with Eslicarbazepine acetate. |
| Esmolol | Procarbazine may increase the hypotensive activities of Esmolol. |
| Estazolam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Estazolam. |
| Estramustine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Estramustine. |
| Eszopiclone | The risk or severity of CNS depression can be increased when Procarbazine is combined with Eszopiclone. |
| Etacrynic acid | Procarbazine may increase the orthostatic hypotensive activities of Etacrynic acid. |
| Etafedrine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Etafedrine. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Procarbazine. |
| Ethanol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ethanol. |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procarbazine. |
| Ethosuximide | The risk or severity of adverse effects can be increased when Ethosuximide is combined with Procarbazine. |
| Ethotoin | The risk or severity of adverse effects can be increased when Ethotoin is combined with Procarbazine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Etidocaine. |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Procarbazine. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Procarbazine. |
| Everolimus | The risk or severity of adverse effects can be increased when Procarbazine is combined with Everolimus. |
| Exenatide | Procarbazine may increase the hypoglycemic activities of Exenatide. |
| Ezogabine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ezogabine. |
| Felbamate | The risk or severity of adverse effects can be increased when Felbamate is combined with Procarbazine. |
| Felodipine | Procarbazine may increase the hypotensive activities of Felodipine. |
| Fenfluramine | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Fenfluramine. |
| Fenofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Procarbazine. |
| Fenofibric acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Fenofibric acid. |
| Fenoldopam | Procarbazine may increase the hypotensive activities of Fenoldopam. |
| Fenoterol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Fenoterol. |
| Fentanyl | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Fentanyl. |
| Fesoterodine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine. |
| Filgotinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Filgotinib. |
| Fingolimod | Procarbazine may increase the immunosuppressive activities of Fingolimod. |
| Flavoxate | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate. |
| Flibanserin | The metabolism of Flibanserin can be decreased when combined with Procarbazine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Procarbazine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Procarbazine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Procarbazine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Procarbazine. |
| Fluindione | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Fluindione. |
| Flunarizine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Flunarizine. |
| Ipratropium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium. |
| Irbesartan | Procarbazine may increase the hypotensive activities of Irbesartan. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Procarbazine. |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Procarbazine is combined with Isocarboxazid. |
| Isoetharine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoetharine. |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Procarbazine. |
| Isometheptene | Procarbazine may increase the sympathomimetic activities of Isometheptene. |
| Isoniazid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Procarbazine. |
| Isoprenaline | The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoprenaline. |
| Isopropamide | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide. |
| Isosorbide dinitrate | Procarbazine may increase the orthostatic hypotensive activities of Isosorbide dinitrate. |
| Isosorbide mononitrate | Procarbazine may increase the orthostatic hypotensive activities of Isosorbide mononitrate. |
| Isotretinoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Procarbazine. |
| Isoxsuprine | Procarbazine may increase the orthostatic hypotensive activities of Isoxsuprine. |
| Isradipine | Procarbazine may increase the hypotensive activities of Isradipine. |
| Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Procarbazine. |
| Ixabepilone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ixabepilone. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ixekizumab. |
| Janssen COVID-19 | The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Procarbazine. |
| Japanese encephalitis | The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Procarbazine. |
| Ketamine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ketamine. |
| Ketazolam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ketazolam. |
| Labetalol | Procarbazine may increase the hypotensive activities of Labetalol. |
| Lacidipine | Procarbazine may increase the hypotensive activities of Lacidipine. |
| Lacosamide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lacosamide. |
| Lamivudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Procarbazine. |
| Lamotrigine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine. |
| Lasmiditan | The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Procarbazine. |
| Leflunomide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Leflunomide. |
| Lemborexant | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lemborexant. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Procarbazine. |
| Lepirudin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin. |
| Lercanidipine | Procarbazine may increase the hypotensive activities of Lercanidipine. |
| Letrozole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Procarbazine. |
| Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Procarbazine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Procarbazine. |
| Levamlodipine | Procarbazine may increase the hypotensive activities of Levamlodipine. |
| Levetiracetam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Levetiracetam. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Levobupivacaine. |
| Levocetirizine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Levocetirizine. |
| Levodopa | Procarbazine may increase the orthostatic hypotensive activities of Levodopa. |
| Levomilnacipran | Procarbazine may increase the serotonergic activities of Levomilnacipran. |
| Levonordefrin | Procarbazine may increase the hypertensive activities of Levonordefrin. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Procarbazine. |
| Levosalbutamol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Levosalbutamol. |
| Levosimendan | Procarbazine may increase the orthostatic hypotensive activities of Levosimendan. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Lidocaine. |
| Linagliptin | Procarbazine may increase the hypoglycemic activities of Linagliptin. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Linezolid. |
| Lipegfilgrastim | Procarbazine may increase the myelosuppressive activities of Lipegfilgrastim. |
| Liraglutide | Procarbazine may increase the hypoglycemic activities of Liraglutide. |
| Lisdexamfetamine | Procarbazine may increase the hypertensive activities of Lisdexamfetamine. |
| Lisinopril | Procarbazine may increase the hypotensive activities of Lisinopril. |
| Lisuride | The metabolism of Lisuride can be decreased when combined with Procarbazine. |
| Lithium carbonate | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Lithium carbonate. |
| Lithium citrate | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Lithium citrate. |
| Lithium hydroxide | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Lithium hydroxide. |
| Lixisenatide | Procarbazine may increase the hypoglycemic activities of Lixisenatide. |
| Lofexidine | The therapeutic efficacy of Procarbazine can be increased when used in combination with Lofexidine. |
| Lomustine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lomustine. |
| Lopinavir | The serum concentration of Procarbazine can be increased when it is combined with Lopinavir. |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Procarbazine. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lorcaserin. |
| Lormetazepam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lormetazepam. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lorpiprazole. |
| Losartan | Procarbazine may increase the hypotensive activities of Losartan. |
| Lovastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Procarbazine. |
| Loxapine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Loxapine. |
| Lumateperone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lumateperone. |
| Lurasidone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone. |
| Macitentan | Procarbazine may increase the hypotensive activities of Macitentan. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Procarbazine. |
| Magnesium sulfate | The therapeutic efficacy of Procarbazine can be increased when used in combination with Magnesium sulfate. |
| Manidipine | Procarbazine may increase the hypotensive activities of Manidipine. |
| Mannitol | Procarbazine may increase the orthostatic hypotensive activities of Mannitol. |
| Maprotiline | The risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Procarbazine. |
| Measles virus | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Procarbazine. |
| Mebeverine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine. |
| Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Procarbazine. |
| Moricizine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Moricizine. |
| Morphine | Procarbazine may increase the analgesic activities of Morphine. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Mosunetuzumab. |
| Moxonidine | Procarbazine may increase the hypotensive activities of Moxonidine. |
| Mumps virus | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Procarbazine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Procarbazine. |
| Muzolimine | Procarbazine may increase the hypotensive activities of Muzolimine. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Procarbazine. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Procarbazine. |
| Niacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Procarbazine. |
| Nialamide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Nialamide. |
| Nicardipine | Procarbazine may increase the hypotensive activities of Nicardipine. |
| Nicorandil | Procarbazine may increase the hypotensive activities of Nicorandil. |
| Nifedipine | Procarbazine may increase the orthostatic hypotensive activities of Nifedipine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Nilotinib. |
| Nilvadipine | Procarbazine may increase the hypotensive activities of Nilvadipine. |
| Nimesulide | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Nimesulide. |
| Nimodipine | Procarbazine may increase the hypotensive activities of Nimodipine. |
| Nisoldipine | Procarbazine may increase the hypotensive activities of Nisoldipine. |
| Nitrazepam | The risk or severity of adverse effects can be increased when Procarbazine is combined with Nitrazepam. |
| Nitrendipine | Procarbazine may increase the hypotensive activities of Nitrendipine. |
| Nitric Oxide | Procarbazine may increase the orthostatic hypotensive activities of Nitric Oxide. |
| Nitroglycerin | Procarbazine may increase the hypotensive activities of Nitroglycerin. |
| Nitroprusside | Procarbazine may increase the hypotensive activities of Nitroprusside. |
| Nitrous acid | Procarbazine may increase the orthostatic hypotensive activities of Nitrous acid. |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Procarbazine. |
| Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Procarbazine. |
| Nomifensine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Nomifensine. |
| Norepinephrine | Procarbazine may increase the hypertensive activities of Norepinephrine. |
| Norfloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Procarbazine. |
| Normethadone | The risk or severity of adverse effects can be increased when Normethadone is combined with Procarbazine. |
| Nortriptyline | Procarbazine may increase the serotonergic activities of Nortriptyline. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Procarbazine. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Obinutuzumab. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ocrelizumab. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ofatumumab. |
| Ofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Procarbazine. |
| Olanzapine | Procarbazine may increase the orthostatic hypotensive activities of Olanzapine. |
| Olaparib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Olaparib. |
| Oliceridine | The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Procarbazine is combined with Oliceridine. |
| Olmesartan | Procarbazine may increase the hypotensive activities of Olmesartan. |
| Olodaterol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Olodaterol. |
| Ondansetron | The risk or severity of adverse effects can be increased when Ondansetron is combined with Procarbazine. |
| Opicapone | Procarbazine may increase the orthostatic hypotensive activities of Opicapone. |
| Opium | The risk or severity of adverse effects can be increased when Opium is combined with Procarbazine. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Procarbazine is combined with Orciprenaline. |
| Orphenadrine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Procarbazine. |
| Oxazepam | The risk or severity of adverse effects can be increased when Oxazepam is combined with Procarbazine. |
| Oxcarbazepine | The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Procarbazine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Oxetacaine. |
| Oxitriptan | The risk or severity of adverse effects can be increased when Procarbazine is combined with Oxitriptan. |
| Oxprenolol | Procarbazine may increase the hypotensive activities of Oxprenolol. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Oxybuprocaine. |
| Oxybutynin | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin. |
| Oxycodone | Procarbazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone. |
| Oxymetazoline | The serum concentration of Oxymetazoline can be increased when it is combined with Procarbazine. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Procarbazine. |
| Oxyphencyclimine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine. |
| Oxyphenonium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium. |
| Ozanimod | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Procarbazine is combined with Paclitaxel. |
| Palbociclib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Procarbazine. |
| Paliperidone | The risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone. |
| Palonosetron | The risk or severity of adverse effects can be increased when Palonosetron is combined with Procarbazine. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Procarbazine. |
| Pancuronium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium. |
| Panobinostat | The risk or severity of adverse effects can be increased when Procarbazine is combined with Panobinostat. |
| Papaverine | Procarbazine may increase the orthostatic hypotensive activities of Papaverine. |
| Paraldehyde | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Paramethadione | The risk or severity of adverse effects can be increased when Paramethadione is combined with Procarbazine. |
| Pargyline | The risk or severity of adverse effects can be increased when Procarbazine is combined with Pargyline. |
| Parnaparin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Parnaparin. |
| Paroxetine | Procarbazine may increase the serotonergic activities of Paroxetine. |
| Pazopanib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Pazopanib. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Procarbazine. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Procarbazine is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Procarbazine. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Procarbazine. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Procarbazine. |
| Peginterferon beta-1a | The risk or severity of adverse effects can be increased when Procarbazine is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Procarbazine. |
| Penbutolol | Procarbazine may increase the hypotensive activities of Penbutolol. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Procarbazine. |
| Pentamidine | Procarbazine may increase the hypoglycemic activities of Pentamidine. |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentazocine is combined with Procarbazine. |
| Pentobarbital | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Procarbazine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Procarbazine. |
| Rivaroxaban | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Rivaroxaban. |
| Rizatriptan | The metabolism of Rizatriptan can be decreased when combined with Procarbazine. |
| Rocuronium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Procarbazine. |
| Ropeginterferon alfa-2b | The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Procarbazine. |
| Ropinirole | Procarbazine may increase the sedative activities of Ropinirole. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Ropivacaine. |
| Rosiglitazone | Procarbazine may increase the hypoglycemic activities of Rosiglitazone. |
| Rosuvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Rosuvastatin is combined with Procarbazine. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Procarbazine. |
| Rotigotine | Procarbazine may increase the sedative activities of Rotigotine. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Procarbazine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Procarbazine. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ruxolitinib. |
| Sacubitril | Procarbazine may increase the orthostatic hypotensive activities of Sacubitril. |
| Safinamide | The risk or severity of adverse effects can be increased when Procarbazine is combined with Safinamide. |
| Salbutamol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Salbutamol. |
| Salmeterol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Procarbazine. |
| Saquinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Saquinavir. |
| Sarilumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Satralizumab. |
| Saxagliptin | Procarbazine may increase the hypoglycemic activities of Saxagliptin. |
| Scopolamine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine. |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Procarbazine. |
| Secukinumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Secukinumab. |
| Selegiline | The risk or severity of adverse effects can be increased when Selegiline is combined with Procarbazine. |
| Selexipag | Procarbazine may increase the hypotensive activities of Selexipag. |
| Semaglutide | Procarbazine may increase the hypoglycemic activities of Semaglutide. |
| Serdexmethylphenidate | The risk or severity of adverse effects can be increased when Procarbazine is combined with Serdexmethylphenidate. |
| Sertindole | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sertindole. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Procarbazine. |
| Sevoflurane | The risk or severity of adverse effects can be increased when Sevoflurane is combined with Procarbazine. |
| Sibutramine | Procarbazine may increase the serotonergic activities of Sibutramine. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Procarbazine. |
| Siltuximab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Siltuximab. |
| Simvastatin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Procarbazine. |
| Siponimod | The risk or severity of adverse effects can be increased when Procarbazine is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Procarbazine. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Procarbazine. |
| Sitagliptin | Procarbazine may increase the hypoglycemic activities of Sitagliptin. |
| Sitaxentan | Procarbazine may increase the hypotensive activities of Sitaxentan. |
| Smallpox (Vaccinia) | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Procarbazine. |
| Sodium citrate | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sodium citrate. |
| Sodium oxybate | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Solifenacin | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin. |
| Solriamfetol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Solriamfetol. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Procarbazine. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Procarbazine. |
| Sotagliflozin | Procarbazine may increase the hypoglycemic activities of Sotagliflozin. |
| Sotalol | Procarbazine may increase the orthostatic hypotensive activities of Sotalol. |
| Spesolimab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Spesolimab. |
| Spirapril | Procarbazine may increase the hypotensive activities of Spirapril. |
| Spironolactone | Procarbazine may increase the orthostatic hypotensive activities of Spironolactone. |
| St. John’s Wort | The risk or severity of adverse effects can be increased when Procarbazine is combined with St. John’s Wort. |
| Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Procarbazine. |
| Stiripentol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Stiripentol. |
| Streptokinase | Procarbazine may increase the orthostatic hypotensive activities of Streptokinase. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Procarbazine. |
| Succinylcholine | The risk or severity of adverse effects can be increased when Succinylcholine is combined with Procarbazine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Procarbazine. |
| Sulfadiazine | Procarbazine may increase the hypoglycemic activities of Sulfadiazine. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Procarbazine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Procarbazine. |
| Sulfinpyrazone | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sulfinpyrazone. |
| Sulfisoxazole | Procarbazine may increase the hypoglycemic activities of Sulfisoxazole. |
| Sulodexide | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sulodexide. |
| Sulpiride | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride. |
| Sulthiame | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sulthiame. |
| Sultopride | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sultopride. |
| Sumatriptan | The metabolism of Sumatriptan can be decreased when combined with Procarbazine. |
| Sunitinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sunitinib. |
| Suvorexant | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thiopental | Procarbazine may increase the orthostatic hypotensive activities of Thiopental. |
| Thioridazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Thioridazine. |
| Thiotepa | The risk or severity of adverse effects can be increased when Procarbazine is combined with Thiotepa. |
| Thiothixene | The risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene. |
| Thonzylamine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. |
| Tiagabine | The risk or severity of adverse effects can be increased when Tiagabine is combined with Procarbazine. |
| Ticagrelor | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ticagrelor. |
| Tick-borne encephalitis | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Procarbazine. |
| Ticlopidine | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ticlopidine. |
| Timolol | Procarbazine may increase the hypotensive activities of Timolol. |
| Tinzaparin | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Tinzaparin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Procarbazine. |
| Tiotropium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Tiotropium. |
| Tirofiban | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Tirofiban. |
| Tirzepatide | Procarbazine may increase the hypoglycemic activities of Tirzepatide. |
| Tixocortol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Tixocortol. |
| Tizanidine | Procarbazine may increase the orthostatic hypotensive activities of Tizanidine. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Tocilizumab. |
| Tofacitinib | Procarbazine may increase the immunosuppressive activities of Tofacitinib. |
| Tolazamide | Procarbazine may increase the hypoglycemic activities of Tolazamide. |
| Tolazoline | Procarbazine may increase the hypotensive activities of Tolazoline. |
| Tolbutamide | Procarbazine may increase the hypoglycemic activities of Tolbutamide. |
| Tolcapone | Procarbazine may increase the orthostatic hypotensive activities of Tolcapone. |
| Tolterodine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine. |
| Topiramate | The risk or severity of adverse effects can be increased when Topiramate is combined with Procarbazine. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Procarbazine. |
| Torasemide | Procarbazine may increase the hypotensive activities of Torasemide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Procarbazine. |
| Trabectedin | The risk or severity of adverse effects can be increased when Procarbazine is combined with Trabectedin. |
| Tramadol | The risk or severity of serotonin syndrome and seizure can be increased when Procarbazine is combined with Tramadol. |
| Trandolapril | Procarbazine may increase the hypotensive activities of Trandolapril. |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Procarbazine. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Trastuzumab emtansine. |
| Trazodone | Procarbazine may increase the serotonergic activities of Trazodone. |
| Treprostinil | Procarbazine may increase the hypotensive activities of Treprostinil. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tretinoin is combined with Procarbazine. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Procarbazine. |
| Triamterene | Procarbazine may increase the orthostatic hypotensive activities of Triamterene. |
| Triazolam | The risk or severity of adverse effects can be increased when Triazolam is combined with Procarbazine. |
| Trichlormethiazide | Procarbazine may increase the hypotensive activities of Trichlormethiazide. |
| Trichloroethylene | The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Procarbazine. |
| Triclofos | The risk or severity of adverse effects can be increased when Procarbazine is combined with Triclofos. |
| Trifluoperazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Trifluoperazine. |
| Triflupromazine | The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Triflupromazine. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Procarbazine. |
| Triflusal | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Triflusal. |
| Trihexyphenidyl | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl. |
| Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Procarbazine. |
| Trimebutine | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine. |
| Trimethadione | The risk or severity of adverse effects can be increased when Trimethadione is combined with Procarbazine. |
| Trimethaphan | Procarbazine may increase the hypotensive activities of Trimethaphan. |
| Trimethobenzamide | The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Procarbazine. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Procarbazine. |
| Trimipramine | Procarbazine may increase the serotonergic activities of Trimipramine. |
| Triprolidine | The risk or severity of adverse effects can be increased when Triprolidine is combined with Procarbazine. |
| Troglitazone | Procarbazine may increase the hypoglycemic activities of Troglitazone. |
| Tropisetron | The risk or severity of adverse effects can be increased when Procarbazine is combined with Tropisetron. |
| Trospium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trospium. |
| Tryptophan | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Procarbazine. |
| Tubocurarine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Tubocurarine. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Procarbazine. |
| Typhoid Vaccine Live | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Procarbazine. |
| Typhoid Vi polysaccharide | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Procarbazine. |
| Ubidecarenone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Ubidecarenone. |
| Umeclidinium | Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Procarbazine is combined with Upadacitinib. |
| Urethane | The risk or severity of adverse effects can be increased when Procarbazine is combined with Urethane. |
| Urokinase | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Urokinase. |
| Valproate bismuth | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Valproate bismuth. |
| Valproic acid | The risk or severity of adverse effects can be increased when Valproic acid is combined with Procarbazine. |
| Valsartan | Procarbazine may increase the hypotensive activities of Valsartan. |
| Varicella zoster vaccine | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Procarbazine. |
| Varicella zoster vaccine | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Procarbazine. |
| Vecuronium | The risk or severity of adverse effects can be increased when Procarbazine is combined with Vecuronium. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Procarbazine is combined with Vedolizumab. |
| Venlafaxine | The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Venlafaxine. |
| Verapamil | Procarbazine may increase the orthostatic hypotensive activities of Verapamil. |
| Vericiguat | Procarbazine may increase the orthostatic hypotensive activities of Vericiguat. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Procarbazine. |
| Vigabatrin | The risk or severity of adverse effects can be increased when Vigabatrin is combined with Procarbazine. |
| Vilanterol | The risk or severity of adverse effects can be increased when Procarbazine is combined with Vilanterol. |
| Vilazodone | The metabolism of Vilazodone can be decreased when combined with Procarbazine. |
| Vildagliptin | Procarbazine may increase the hypoglycemic activities of Vildagliptin. |
| Viloxazine | The risk or severity of hypertension can be increased when Viloxazine is combined with Procarbazine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Procarbazine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Procarbazine. |
Pregnancy and Lactation
FDA Pregnancy Category D
Pregnancy
There is a possibility of birth defects if either the father or mother is taking procarbazine at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately.
Breast-feeding
It is not known if procarbazine passes into breast milk. If you are a breast-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
How should this medicine be used?
Procarbazine comes as a capsule to take by mouth. It is usually taken one or more times a day. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Take procarbazine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take procarbazine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may adjust your dose of procarbazine or stop your treatment for a period of time depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.
What special precautions should I follow?
Before taking procarbazine,
- tell your doctor and pharmacist if you are allergic to procarbazine, any other medications, or any of the ingredients in procarbazine capsules. Ask your pharmacist for a list of the ingredients.
- tell your doctor if you are taking or you plan to take any of the following prescription or non-prescription medications: certain antidepressants including amitriptyline (Elavil) and imipramine (Tofranil); medications for asthma; medications for allergies, hay fever; medications containing alcohol (cough and cold products, such as Nyquil, and other liquid products); and nasal decongestants, including nose drops and sprays. Your doctor may tell you not to take these medications with procarbazine and may suggest other treatment(s).
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: barbiturate medications such as phenobarbital; medications for high blood pressure; medications for nausea or mental illness; opioid (narcotic) medications for pain; sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with procarbazine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you have received radiation therapy or other chemotherapy within the last 4 weeks.
- tell your doctor if you have or have ever had kidney or liver disease.
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You should not become pregnant or breast-feed while you are taking procarbazine. If you become pregnant while receiving procarbazine, call your doctor. Procarbazine may harm the fetus.
- know that you should not drink alcoholic beverages (including beer and wine) while taking this drug. Alcohol may cause an upset stomach, vomiting, stomach cramps, headaches, sweating, and flushing (redness of the face).
- tell your doctor if you use tobacco products. Smoking may increase the risk that you will develop other cancers. You should stop smoking.
References
